SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Aug. 7, 2020-- Veracyte, Inc. (Nasdaq: VCYT) announced today the closing of its public offering of 6,900,000 shares of common stock, including 900,000 shares sold upon full exercise of the underwriters’ option to purchase additional shares, at a price
ePosters presented during ATS 2020 Virtual conference SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Aug. 5, 2020-- Veracyte, Inc . (Nasdaq: VCYT) announced today that data presented at the American Thoracic Society 2020 Virtual conference reinforce the potential clinical value of the company’s
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Aug. 5, 2020-- Veracyte, Inc . (Nasdaq: VCYT) today announced the publication of new data demonstrating that the Percepta ® classifier significantly reduces invasive procedures in lung cancer diagnosis by classifying nearly 40 percent of patients as
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Aug. 4, 2020-- Veracyte, Inc. (Nasdaq: VCYT) (the “Company”) today announced the pricing of an underwritten public offering of 6,000,000 shares of its common stock at a public offering price of $30.00 per share.
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Aug. 3, 2020-- Veracyte, Inc. (Nasdaq: VCYT) (the “Company”) today announced that it has commenced an underwritten public offering of 6,000,000 shares of its common stock. All of the shares are being offered by Veracyte .
Revenue of $20.7 Million and Genomic Testing Volume of 5,379 Company Advances Pipeline and Global Expansion Strategy Conference Call and Webcast Today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jul. 30, 2020-- Veracyte, Inc . (Nasdaq: VCYT) today announced financial results for
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jul. 30, 2020-- Veracyte, Inc . (Nasdaq: VCYT) today announced new study results showing that use of the Envisia ® Genomic Classifier improves physicians’ ability to diagnose idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases
Novel approach may enable processing of over 40,000 patient samples per day using molecular barcodes for viral RNA SOUTH SAN FRANCISCO, Calif. , and MIAMI --(BUSINESS WIRE)--Jul. 29, 2020-- Veracyte, Inc . (Nasdaq: VCYT) and MAVIDx today announced an agreement for MAVIDx to develop ultra-high
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jul. 27, 2020-- Veracyte, Inc. (Nasdaq: VCYT), a global genomic diagnostics company, today announced the addition of Jens Holstein to the company’s board of directors and the appointment of Jim Erlinger as executive vice president, general counsel and
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jul. 16, 2020-- Veracyte, Inc . (Nasdaq: VCYT) announced today that it will release its financial results for the second quarter of 2020 after the close of market on Thursday, July 30, 2020 . Company management will host a conference call and webcast
The information in our press releases and webcasts should be considered accurate only as of the date of the press release or presentation. We disclaim any obligation to supplement or update the information in these press releases or presentations.
